Join Growin Stock Community!

Abeona therapeutics inc.ABEO.US Overview

US StockHealthcare
(No presentation for ABEO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABEO AI Insights

ABEO Overall Performance

ABEO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABEO Recent Performance

-1.07%

Abeona therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

ABEO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABEO Key Information

ABEO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABEO Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Price of ABEO

ABEO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABEO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.52
PE Ratio (TTM)
4.23
Forward PE
-
PS Ratio (TTM)
693.65
PB Ratio
1.62
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-22.00%
Net Margin
20587.50%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.52
PE Ratio (TTM)
4.23
Forward PE
-
PS Ratio (TTM)
693.65
PB Ratio
1.62
Price-to-FCF
-
Gross Margin
-22.00%
Net Margin
20587.50%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ABEO's latest earnings report released?

    The most recent financial report for Abeona therapeutics inc. (ABEO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABEO's short-term business performance and financial health. For the latest updates on ABEO's earnings releases, visit this page regularly.

  • Where does ABEO fall in the P/E River chart?

    According to historical valuation range analysis, Abeona therapeutics inc. (ABEO)'s current price-to-earnings (P/E) ratio is 3.25, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much debt does ABEO have?

    As of the end of the reporting period, Abeona therapeutics inc. (ABEO) had total debt of 24.11M, with a debt ratio of 0.1. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ABEO have?

    At the end of the period, Abeona therapeutics inc. (ABEO) held Total Cash and Cash Equivalents of 83.22M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ABEO's EPS continuing to grow?

    According to the past four quarterly reports, Abeona therapeutics inc. (ABEO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ABEO?

    Abeona therapeutics inc. (ABEO)'s Free Cash Flow (FCF) for the period is -23.71M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 87.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ABEO?

    The latest valuation data shows Abeona therapeutics inc. (ABEO) has a Price-To-Earnings (PE) ratio of 3.25 and a Price/Earnings-To-Growth (PEG) ratio of 0.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.